Low molecular weight heparins and fondaparinux in therapy of antiphospholipid syndrome: laboratory control and application: 616-005.6:616.151.5:612.115.3

Abstract

Therapy of antiphospholipid syndrome (APS) is a lifelong primary and secondary prophylaxis of thromboses. Due to appearance of new anticoagulants question of antithrombotic therapy choosing became more complicated. Optimization of anticoagulants selection at APS according pathogenesis, existing risk factors and comorbidity is discussed. Advantages and indications for regular monitoring of plasma anti-Xa activity at patients with primary and secondary APS are presented.

REFERENCES

1. Nasonov E. L. Antiphospholipid syndrome [Antifosfolipidnyj sindrom]. Moskva: Litterra. 2004: 440 s (in Russ.).
2. Reshetnyak Т. М. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture) [Antifosfolipidnyj sindrom: diagnostika i klinicheskie proyavleniya (lekciya)]. Nauchnoprakticheskaya revmatologiya. 2014; 52 (1): 56–71 (in Russ.).
3. Nasonova V. A. Systemic lupus erythematosus [Sistemnaya krasnaya volchanka]. Moskva: Medicina. 1972: 248 s (in Russ.).
4. Smythe M. A., Priziola J., Dobesh P. P. et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016; 41 (1): 165–86.
5. Garcia D. A., Baglin T. P., Weitz J. I. et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141 (Suppl 2): e24S-e43S.
6. Babin J. L., Traylor K. L., Witt D. M. Laboratory monitoring of low-molecular-weight heparin and fondaparinux. Semin Thromb Hemost. 2016 [Epub ahead of print] (doi: 10.1055/s- 0036–1 581 129).
7. Krichevsky L. A. Low molecular weight heparins in the modern blood coagulability management system [Nizkomolekulyarnye gepariny v sovremennoj sisteme upravleniya svertyvaemost’yu krovi]. Doktor.Ru. 2015; 15–16 (115-116): 42–8 (in Russ.).
8. Chapman T. M., Goa K. L. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs. 2003; 63 (21): 2357–77.
9. Wellington K., McClellan K., Jarvis B. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. Drugs. 2001; 61 (8): 1185–209.
10. Diener H. C., Ringelstein E. B., von Kummer R. et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of patients with acute stroke (TOPAS) investigators. Stroke. 2001; 32 (1): 22–9.
11. Camporese G., Bernardi E., Noventa F. Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vasc Health Risk Manag. 2009; 5: 819–81.
12. Funk D. M. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program. 2012; 2012: 460– 465 (doi: 10.1182/asheducation-2012.1.460).
13. Duplaga B. A., Rivers C. W., Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001; 21 (2): 218–34.
14. Houbouyan L., Boutière B., Contant G. et al. Validation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins. Clin Chem. 1996; 42 (8): 1223–30.
15. Harris L. F., O’Brien A., Castro-López V. et al. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. Thromb Res. 2011; 128 (6): 166–70.
16. Gehrie E., Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2012; 87 (2): 194–6.
17. Yentz S., Onwuemene O. A., Stein B. L. et al. Clinical use of antiXa monitoring in malignancy-associated thrombosis. Thrombosis. 2015; 2015: Article ID 126 975 (doi: 10.1155/2015/126 975).
18. Kirienko A. I., Panchenko E. P., Andriyashkin V. V. Venous thrombosis in the practice of the therapist and surgeon [Venoznyj tromboz v praktike terapevta i hirurga]. Moskva: Planida. 2012: 336 s (in Russ.).
19. Reshetnyak Т. М. Low molecular weight heparins in the therapy of antiphospholipid syndrome and new perspectives [Nizkomolekulyarnye gepariny v terapii antifosfolipidnogo sindrom i novye perspektivy]. Consilium medicum. 2006; 8 (2): 55–61 (in Russ.).
20. Reshetnyak T. M., Kondratyeva L. V. Pharmacotherapy of antiphospholipid syndrome: the site of heparin preparations [Farmakoterapiya antifosfolipidnogo sindroma: mesto preparatov geparina]. RMZH. 2008; 10: 672–80 (in Russ.).
21. Kondrateva L. V., Reshetnyak Т. М. Antiphospholipid syndrome: diagnosis and prevention of thrombosis [Antifosfolipidnyj sindrom: diagnostika i profilaktika trombozov]. Doktor.Ru. 2010; 3: 52–6 (in Russ.).
22. Chaturvedi S., McCrae K. R. The antiphospholipid syndrome: still an enigma. Hematology Am Soc Hematol Educ Program. 2015; 2015: 53–60 (doi: 10.1182/asheducation-2015.1.53).
23. Siguret V., Gouin-Thibault I., Pautas E. et al. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. J Thromb Haemost. 2011; 9 (10): 1966–72.
24. Weening J. J., D’Agati V. D., Schwartz M. M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15 (2): 241–50.
25. Lockshin M. D., Kim M., Laskin C. A., Leizorovicz A. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012; 64 (7): 2311–8.
26. Chauleur C., Galanaud J. P., Alonso S. et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost. 2010; 8 (4): 699–706.
27. Bates S. M., Greer I. A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (Suppl 2): e691S-e736S.
28. Kamel H., Navi B. B., Sriram N. et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014; 370 (14): 1307–15.
29. Lagrange F., Vergnes C., Brun J. L. et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost. 2002; 87 (5): 831–5.
30. Dempfle C. E. Minor transplacental passage of fonda parinux in vivo. N Engl J Med. 2004; 350 (18): 1914–5.
31. Mazzolai L., Hohlfeld P., Spertini F. et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood. 2006; 108 (5): 1569–70.
32. Wijesiriwardana A., Lees D. A., Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis. 2006; 17 (2): 147–9.
33. Gerhardt A., Zotz R. B., Stockschlaeder M., Scharf R. E. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost. 2007; 97 (3); 496–7.
34. Schapkaitz E., Jacobson B. F. Delayed hypersensitivity to lowmolecular-weight heparin (LMWH) in pregnancy. S Afr Med J. 2007; 97 (12): 1255–7.
35. Knol H. M., Schultinge L., Erwich J. J. H. M., Meijer K. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost. 2010; 8 (8): 1876–9.
36. Winger E. E., Reed J. L. A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss. Am J Reprod Immunol. 2009; 62 (4): 253–60.
37. Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb Res. 2007; 119 (3): 385–8.
38. Joalland F., de Boysson H., Darnige L. et al. Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report. Rev Med Interne. 2014; 35 (11); 752–6.
39. Regunath H., Shortridge J., Raza S. et al. Occult pulmonary mucosa-associated lymphoid tissue lymphoma presenting as catastrophic antiphospholipid antibody syndrome. Oncol Lett. 2013; 6 (5): 1261–4.
40. Costa R., Fazal S., Kaplan R. B. et al. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013; 32 (Suppl 1): S79-S82.
41. Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. 2013; 22 (1): 6–17.
42. Alijotas-Reig J., Ferrer-Oliveras R. Management of refractory obstetric antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Proceedings of the 9th Meeting of the European Forum on Antiphospholipid Antibodies. Krakow, Poland. 2013; Medycyna praktyczna, 2013.